Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
611 for Moderate to Severe COPD (Phase III, China)
ChiCTR2500104536Phase 3Not yet recruiting
- Sponsor
- Shenzhen People's Hospital
- Start
- Jun 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing 611 arm with Placebo arm (2 arms). Primary endpoint: Annualized incidence of moderate/severe AECOPD during the 52-week treatment period. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
SSGJ-611
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on ChiCTR2500104536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500104536.